The 15th International Gastric Cancer Congress (IGCC 2023)第15回国際胃癌学会


Call for Abstracts


Absract/Travel Grants acceptance as of March 10


October 5 (Wed) –  November 24 (Thu),
2022 (JST)

 December 19 (Mon), 2022 (JST)

Abstract submission is now closed.
Thank you for your submission.


  • Abstracts are to be submitted electronically via the online submission system by December 19 (Mon), November 24, 2022 (JST).  Abstract submission is now closed. Abstracts received after the deadline will not be accepted and therefore will not be considered for the program.
  • Authors may submit more than one abstract. However, subject to program space, not all abstracts may be accepted.
  • Encore abstracts will be accepted.
  • Authors of all accepted abstracts are expected to register for IGCC 2023 and pay the meeting registration fee. They are also encouraged to pay their IGCA dues.
  • Abstracts can be amended in the online submission system until the submission deadline November 24, 2022 (JST).
  • All successfully submitted abstracts will be reviewed by the IGCC 2023 Program Committee, who will consider its formal aspects and content, and may reconsider the pre-selected presentation type.
  • All accepted abstracts will form part of the final program and will be presented onsite as well as published in the official congress proceedings and congress app/website.
  • All presenting authors are obliged to register. Those who do not register for the Congress and complete payment of the registration fee by the deadline will be automatically withdrawn from the final program.
  • Abstract authors are also required to provide Institutional Review Board (IRB) approval (if applicable) and disclosure of financial relationships at the time of submission (e.g. grants, fees from private companies, shares, paid positions).


Updates of ongoing clinical trials
Session Summary

A number of important trials aimed at improving treatment outcomes for gastric and GEJ cancer are currently underway. In this session, updates on those trials will be presented by their investigators.

Reviewing landmark clinical trials
Session Summary

Multidisciplinary treatments have been developed based on earlier pivotal trials. This session will examine the current advances in gastric/GEJ cancer treatment by reviewing epoch-making clinical trials.

Conversion surgery for metastatic gastric cancer
Session Summary

As treatment outcomes for metastatic gastric cancer improve, the clinical importance of conversion surgery is increasing. In this session, the indications and current evidence for conversion surgery will be reviewed.

Ideal classification and staging modalities for GEJ cancer
Session Summary

Classification and staging of GEJ cancer are vital for providing appropriate treatment. This session will discuss the optimal classification and staging modalities for GEJ cancer.

Diagnosis and treatment strategy poorly cohesive cancer of GEJ
Session Summary

Notably, poorly cohesive cancer of the GEJ is a very challenging disease because it can metastasize in the early stage and is resistant to systemic chemotherapy. In this session, the clinical characteristics and ideal approach for poorly cohesive cancer of the GEJ will be shared.

Overviewing guidelines – East versus West –
Session Summary

Diverse multimodal approaches have developed in different countries in terms of disease incidence, epidemiology, clinical features, and treatment strategy. Differences in the extent of surgery are seen between the East and the West, with the East performing more radical surgery and the West leaning more toward multimodality therapies such as perioperative chemotherapy. This session will share information on the guidelines-related differences, and explore the possibilities for collaboration between the East and the West.

Optimal treatment strategy for gastric cancer in elderly patients
Session Summary

Recently, the number of elderly patients with gastric cancer has been increasing due to population aging. In some cases, modified treatment strategy tailored to patients' comorbidities and their systemic status is considered, with regard to adjuvant chemotherapy or surgical approach. This session will discuss the optimal treatment for elderly patients in this context.

Perioperative treatment for GEJ cancer
Session Summary

Several strategies such as adjuvant doublet chemotherapy based on oral fluoropyrimidine in Japan or preoperative chemotherapy with FLOT in the West are widely used for resectable gastric cancer. However, it appears that no standard for perioperative treatment of GEJ cancer has been established. This session will explore the optimal perioperative treatment of GEJ cancer, including with regard to indication, chemotherapy regimen, and timing.

Treatment of peritoneal disease
Session Summary

Peritoneal metastasis is one of the major types of gastric cancer metastasis. Due to its deteriorating treatment outcomes, various treatment strategies have been developed, including HIPEC and intraperitoneal chemotherapy. In this session, the current practice for peritoneal disease will be discussed.

Laparoscopic/robotic gastrectomy for advanced gastric cancer
Session Summary

Several pivotal trials have established the clinical significance of laparoscopic and robotic gastrectomy for advanced gastric cancer. However, the surgical procedures for advanced gastric cancer differ from those for early stage disease, and have yet to be standardized. In this session, experts will share their surgical procedures as a step toward standardization.

Sharing surgical skills for GEJ cancer (Video session)
Session Summary

There are multiple surgical approaches for GEJ cancer, including transthoracic and transhiatal, based on the tumor location and distribution of lymph node metastasis. Furthermore, various reconstruction procedures exist, including for the same tumor location. In this session, surgical skills for GEJ cancer lymphadenectomy and reconstruction.

Navigation surgery for early gastric cancer
Session Summary

Fluorescent endoscopic surgery using ICG has been widely used for identifying the sentinel lymph node, or determining the extent of lymphadenectomy. It enables us to determine the optimal resection line during gastrectomy, but the present status of navigation surgery and its indication remain unclear. This session will discuss the technique of navigation surgery and its outcomes.

ERAS and nutrition after gastrectomy
Session Summary

Enhanced recovery after surgery (ERAS) is shown to help shorten the length of hospitalization, accelerate postoperative recovery, and reduce surgical stress. The ERAS protocols comprise many items, including pre-operative patient education, and early mobilization and feeding starting from the first postoperative day. The purpose of this session is to discuss the applicability of ERAS and optimal nutrition support after gastrectomy.

Postoperative function, QOL and PROs
Session Summary

In addition to oncological outcomes, health-related quality of life is considered an important endpoint after gastrectomy. Several types of PROs, such as EORTC and FACT, are being used in the measurement of QOL. This session will discuss the optimal PRO for gastric cancer patients, and the feasibility of personalized care for specific patients using these PROs.

Immunotherapy for gastric cancer
Session Summary

Immunotherapy has been accepted as a standard treatment for gastric cancer. The indication and updated evidence for it will be shared.

Current status and future perspective of targeted and systemic therapy for gastric cancer
Session Summary

Targeted therapy for gastric cancer has been improved, especially for HER2 positive subpopulations. In this session, the current status and future outlook for targeted and systemic therapy for gastric cancer will be shared.

Biomarker-driven therapeutics for gastric cancer
Session Summary

To date, the evidence for biomarker-driven targeted therapy for gastric cancer is limited except for trastuzumab in HER2 positive cancers. ICIs are promising anti-PD-1 antibodies and are widely used in clinical practice; however, biomarkers for these ICIs have not been clearly identified. This session will present clinical and basic research outcomes related to biomarkers and discuss the biomarker-driven therapeutic strategy for the next stage.

Pharmacotherapy for GIST (advanced/recurrent)
Session Summary

The approval of imatinib, a KIT/PDGFRA TKI, has led to improvement of treatment for advanced GIST, and subsequently two additional drugs were approved (sunitinib & regorafenib). However, despite the discovery of the detailed molecular mechanisms of GIST and subfractions with rare driver mutations, the development of TKI resistance was inevitable and continues to be a problem. This session will discuss the pharmacotherapy for advanced/metastatic GIST and its future outlook.

Laparoscopy and Endoscopy Cooperative Surgery (LECS) & Endoscopic full thickness resection
Session Summary

Laparoscopy and endoscopy cooperative surgery (LECS) & endoscopic full thickness resection (EFTR) have been accepted as treatment options for submucocal tumors. In this session, their technical principles and applications will be shared.

Early Detection, screening
Session Summary

The most effective way to improve the prognosis of gastric cancer is early detection. In this session, we hope to receive a wide range of presentations on efforts to narrow down high-risk groups using biomarkers, advances in observation methods such as image-enhanced endoscopy, education, and construction of effective screening systems.

Management of Barrett's esophagus
Session Summary

Barrett's esophagus is known to be a precursor of gastro-esophageal junctional adenocarcinoma. Very short-length Barrett's epithelium is often seen even in young subjects, and the individual risk for carcinogenesis remains unclear. This session will discuss appropriate surveillance methods and eradication treatment for Barrett's esophagus.

Endoscopic treatment for Gastric and GEJ cancer
Session Summary

Endoscopic resection for early gastric cancer is an excellent treatment with curative and minimal invasiveness. However, there are still technically challenging lesions, and there are proposals for expanding its indication as a local treatment for elderly patients and patients with comorbidities. In this session, we will discuss the latest findings in endoscopic treatment of gastric and GEJ cancer.

Updates in radiotherapy
Session Summary

Radiotherapy is one of the key modalities for advanced gastric cancer. This session will discuss the current evidence and future outlook for multimodality therapy with radiotherapy for gastric cancer.

Supportive & palliative care
Session Summary

Proactive palliative care is widely known to effectively relieve symptoms and improve the quality of life of gastric cancer patients. However, problems that need to be managed by endoscopy, surgery, or radiotherapy, such as malignant gastric outlet obstruction or severe bleeding, may occur. This session will discuss optimal supportive and palliative therapies for gastric cancer patients.

Refining poorly cohesive cancers
Session Summary

Signet-ring cell was redefined as an independent histological type in the 5th edition of the WHO Classification of Tumors, after being temporarily regarded as a subtype of poorly cohesive carcinoma in the 4th edition. The consideration of subtype-specific medical therapy for gastric cancer is becoming increasingly important. This session will examine the refinement of poorly cohesive cancers in the WHO classification and its impact.

Molecular and pathological classifications of Gastric and GEJ cancer
Session Summary

Now that molecular profiling has been established, it now needs to be merged into a pathological classification that is the golden standard. In this session, the ideal molecular and pathological classifications for gastric and GEJ cancer will be discussed.

Omics medicine for gastric cancer
Session Summary

Comprehensive approach is one of the representative tactics for translational research. The current status of omic medicine combining genomics, proteomics, and metabolomics will be presented.

Advances in precision medicine, genomic profiling, and imaging technique
Session Summary

Advances in translational research have improved the treatment outcomes for gastric cancer. Precision medicine with genomic profiling is guiding personalized treatment strategy, and imaging technique that improves the accuracy of cancer detection is facilitating minimally invasive approach. The current status and future outlook of precision medicine will be discussed.

Updates of liquid biopsy for gastric cancer
Session Summary

Liquid biopsy is a promising new diagnostic method with the potential to revolutionize the prevention, diagnosis, and treatment of solid tumors. However, several barriers need to be overcome for its clinical application. This session will present the latest technical developments and data on liquid biopsy in gastric cancer.

Artificial intelligence in the management of gastric cancer
Session Summary

Developments in AI technology have enabled optimal decision-making in diagnostic imaging, endoscopy, and pathology. In recent years, AI-based surgical systems have also begun to be constructed. This session will clarify how AI is being used in the fields of gastric cancer, and its impact and challenges.

Gastric Cancer Care in low-income settings
Session Summary

Access to oncologic treatment varies across countries due to the large differences in healthcare economics. This session will focus on the screening and treatment systems in low-income settings and discuss how to improve access to care.

Hereditary gastric cancer (prevention and treatment)
Session Summary

Hereditary gastric cancer is specific subgroup of gastric cancer that requires multidisciplinary approaches, including screening, treatment, follow-up, and genomic counseling. This session will provide an overview of the optimal approaches for hereditary gastric cancer.

Public policy 'access to care' – Financial background of society and centralization –
Session Summary

Socioeconomic inequalities in gastric cancer survival rates are observed due to differences in stage at diagnosis, gastric cancer subtypes, and access to and use of effective treatments. This session will discuss access to gastric cancer care in the context of the social background.

Patient advocacy session
Session Summary

Developing patient advocacy is important for providing accurate information to patients and ensuring that their views are reflected in healthcare decision-making. This session will be a good opportunity to promote patient advocacy programs, services, and resources to oncologists.

Contributions of big data science to gastric cancer treatment
Session Summary

Big data has been accumulated through the initiatives of various academic societies, and several important findings using that big data have been reported. In this session, we will discuss how to utilize big data in daily clinical practice.


2Molecular biology
5Translational research
7Tumor microenvironment
9Endoscopic therapy
10Endoscopic diagnosis
11Imaging diagnosis
13Progression of gastric cancer
14Rare metastasis / Micrometastasis
15Intraoperative frozen section
16Cancer stem cell
17Clinical pathology
18Prognostic factor
19Precision medicine
20Clinical study
22Neoadjuvant chemotherapy
23Adjuvant chemotherapy
24Second-line chemotherapy
25Third-line chemotherapy
26Intraperitoneal chemotherapy
27Molecular targeted therapy
29Radiation therapy
30conversion surgery
32Laparoscopic surgery
33Robot surgery
34Function-preserving surgery
35Cytoreductive surgery
37Surgical navigation
38Postoperative functional assessment
39Postgastrectomy syndrome
40Perioperative management
41Postoperative complications
43Navigation Surgery
44Peritoneal dissemination
46Stent placement
47Liver metastasis
49Early gastric cancer
50Advanced gastric cancer
51Scirrhous gastric cancer
52Gastric stump carcinoma
53Multiple gastric cancers
54Gastric tube cancer
55Esophago-gastric junction cancer
56Gastric cancer in elderly patients
57AFP-producing gastric cancer
58EBV-related gastric cancer
59Gastrointestinal stromal tumor
60Malignant lymphoma
61Gastric neuroendocrine tumor
63Clinical pathway
64Postoperative surveillance
65Long-term survival case after chemotherapy
68QOL assessment
72Case report
73Japanese Classification of Gastric Carcinoma
74Multidisciplinary treatment
75Palliative therapy
76Team approach
77Patient Advocacy
78MDT conference
79Medical cooperation
80Oral care


Language: English

Title: The title should be entered in upper case and is limited to 100 characters. Abbreviations may not be used in the title. Use generic product names in the title.

Authors: Up to 20 authors can be submitted under one abstract (including presenting author). The presenting author is entered first; other authors can be added only after the presenting author is entered. However, the order of authors can be changed if needed by swapping the names in the list of the co-authors.

Maximum Length: 2,000 characters, excluding the title or spaces.


All abstracts must be structured as follows.

The introduction should be 2 or 3 brief sentences describing the objectives of the study.

A description of the methods used to conduct the study must be included (e.g.,retrospective review, prospective trial). Detailed descriptions of laboratory techniques should not be included. Do not mention the institution where the work was performed in the body or title of the abstract.

The results should occupy one-half to two-thirds of the abstract, and include specific data necessary for evaluating the abstract. If there is reason to believe that additional data would enhance the abstract, then please strongly consider including them. Statements such as “data will be discussed at the presentation” are grounds for disqualification.

The conclusion should be no more than 2 or 3 sentences describing the significance of the results in the context of the original objectives.

  • Please have your abstract checked for spelling, punctuation, grammar and formal structure.
  • The organizers reserve the right to edit abstracts if necessary prior to publication.
  • The abstract may be supplemented with one figure or table.


We invite you to apply for a meeting travel grantas described below. To apply, select "Apply" at the time of abstract submission.

  1. Eligibility
    • The applicant must be aged 40 or under at the time of abstract submission.
    • The applicant must be working or training in a country other than Japan.
    • The applicant may submit only one abstract.
  2. The meeting registration fee will be waived for those who are awarded the travel grant. However, awardees are responsible for arranging their transportation, accommodations, etc.
  3. The Congress President reserves the right to accept/reject any presentations submitted.
  4. Non-Japanese nationals are responsible for obtaining the proper visa to enter Japan.
  5. Applicants will be individually notified of travel grant decisions by February 2023.


Congress Secretariat
c/o Japan Convention Services, Inc.
Tel: +81-3-3508-1214
Email: pgm-igcc2023[A]convention[D]co[D]jp( Please change [A] to @ and [D] to. )